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SUMMARY According to the hypothesis on the stimulating effect of 
adenosine on increasing fibroblast growth factor 7 in dermal papilla 
cells and its vasorelaxant effect, we performed this study to compare 
the effect of topical minoxidil 5% and adenosine 0.75% on male pattern 
androgenetic alopecia. This prospective-randomized study recruited 
110 male patients suffering from grade II-V Hamilton androgenetic alo-
pecia. Fifty-five patients received minoxidil 5% (group 1) and adenos-
ine 0.75% (group 2) each. Later, 16 patients were excluded due to al-
lergic reactions or loss to follow up. After 3 and 6 months of treatment, 
complete and relative recovery rates alongside patient satisfaction rate 
(faster prevention of primary hair loss and appearance of newly grown 
hair) were compared between the groups. After 3 months of treat-
ment, relative recovery was achieved in 2.4% and 1.9% of patients in 
group 1 and group 2, respectively, which was not significantly different 
(p=0.17). During 6 months, the relative recovery rate did not change 
either within or between the groups (p=0.99) and after 6 months none 
of the patients achieved complete recovery. However, the patient sat-
isfaction rate was significantly higher in group 2 (p=0.003). In the light 
of the results, adenosine has no statistically superiority to minoxidil in 
the treatment of androgenetic alopecia according to recovery rates. 
However, the patients were significantly more satisfied with adenosine 
because of faster prevention of hair loss and appearance of the newly 
grown hairs. It seems further studies with larger sample size or different 
drug dosages are required to clarify the findings.
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InTRodUCTIon
Androgenetic alopecia (AGA) or male pattern 
hair loss is still the imperative cause of alopecia that 
revealed an obvious tendency to involve half of the 
population before the age of 50 years (1-5). AGA in 
general is a hereditary thinning of the scalp hairs by 
vellus transformation of the terminal hairs due to 
over repetition of hair growth cycles with shortened 
anagen phase and miniaturization of the hair follicles 
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(3,6,7). Since 1942, when Hamilton first demonstrated 
that this polygenic inheritance process is mediated 
mainly by androgen (8), several studies have focused 
on the hair growth cycle physiology and AGA patho-
physiology (2,3,5,9,10). Hair growth cycle is regulated 
by complex processes, which are the consequences 
of follicular stem cell and dermal papilla cell (DPC) 
interactions (9). On the other hand, frontal scalp 
DPCs are the main target cells of androgen action in 
AGA (9,10). Androgen binds to the androgen recep-
tors and the complex then activates the responsible 
genes that control hair growth cycles. Consequently, 
the duration of anagen phase would be shorter and 
the follicles become miniaturized and produce fine, 
shorter and less pigmented vellus hairs that are the 
characteristics of AGA (2,9). In recent years, quite a 
lot of studies have focused on various pharmacologi-
cal approaches such as minoxidil and finasteride to 
prevent excessive hair loss, promote hair growth and 
enlarge existing hairs by affecting hair growth cycle 
in AGA (2,4,9,11-13). Until now, a variety of different 
direct and indirect effects of minoxidil on hair growth 
cycle have been studied, such as up-regulating vas-
cular endothelial growth factor (VEGF) expression 
through development of follicular dermal papilla cell 
vascularization or its direct effects on the prolifera-
tion and survival of DPCs and anti-apoptotic effects 
on DPCs (11,14,15). Minoxidil is still in the first line 
of treatment of AGA; however, in recent decade and 
since 2001 when Li et al. (16) reported the correlation 
between minoxidil and adenosine, scientists have re-
vealed a noticeable tendency to focus on the adenos-
ine characteristics. In this study, we evaluated the ef-
fect of topical minoxidil 5% and adenosine 0.75% on 
recovery of male pattern AGA. 
MATERIAlS And METhodS
Study population
This randomized prospective study recruited 110 
adult male patients who suffered from grade II to V 
Hamilton-Norwood clinical scale AGA (1) and were re-
ferred to Hair and Skin Disease Clinic of our hospital. 
The study was approved by the hospital ethics com-
mittee, and a written inform consent was obtained 
from the patients. Age under 18 years and presence 
of any signs and symptoms of inflammation or infec-
tion on the scalp, hypersensitivity to minoxidil/ade-
nosine, and history of hypertension and cardiovascu-
lar diseases were considered as exclusion criteria for 
the study. Also, if any patient was lost to follow up or 
experienced allergic reaction or severe complication 
following treatment such as hypertrichosis or exten-
sive hair loss, he was excluded from the study. A total 
of 110 patients were studied and randomly divided 
into 2 groups: 55 patients received minoxidil 5% 
(group 1) and another 55 patients received adenos-
ine 0.75% (group 2). Later, two patients from group 1 
and 14 patients from group 2 were excluded from the 
study due to allergic reaction to the drug or loss to 
follow up. So, 94 patients, i.e. 53 (56.4%) group 1 and 
41 (43.6%) group 2 patients, remained in the study 
and were included in analysis. 
Formulation of the drugs
Minoxidil solution was formulated by dissolving 
5% minoxidil in a solution of alcohol 60% vol/vol, 
propylene glycol, and water and adenosine solution 
was formulated by dissolving 0.75% adenosine in ul-
trapure water. Subjects were instructed to apply ap-
proximately 1 cc of a lotion topically on the scalp (mi-
noxidil 5% in group 1 and adenosine 0.75% in group 
2), twice daily for 6 months.
hair counting
Macro-photography of scalps was performed at 
baseline and then at 3 and 6 months of treatment. 
The photographs were converted into dot maps to 
determine the entire thinning area and counting all 
visible terminal hairs at a 1-cm2 target evaluation site 
within thinning area of each of the four quadrants 
of the frontoparietal and occipitoparietal scalp. The 
three well-trained physicians, who were blinded to 
treatment, performed all evaluations. The mean rat-
ings of the three investigators represented the evalu-
ated factor. 
Recovery scoring 
Complete recovery following treatment was de-
fined as returning hair growth in 65% to 100% of 
the thinning area. Relative recovery was defined as 
returning hair growth in 30% to 65% of the affected 
area. Hair growth returning in less than 30% of the 
thinning area was considered as no recovery or treat-
ment failure. 
Patient satisfaction
Patient satisfaction was based on the ability of 
the drug to prevent primary hair loss faster, stimulate 
growing more pigmented and thick hair with more 
similar characteristics of terminal hairs, and prevent 
hair loss recurrence following treatment discontinu-
ation.
Complications
Folliculitis, pruritus, hair loss and hair casts were 
considered as major complications of treatment. 
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Statistical analysis 
The univariate analysis of continuous variables 
was performed with the Student’s t test, and cat-
egorical variables were compared using the χ2-test 
and Fisher exact test, as appropriate. For statistical 
analyses, SPSS version 16.0 (SPSS Inc., Chicago, IL) 
was used. All p values were 2-tailed. A p value of less 
than 0.05 was considered significant.
RESUlTS
The study included 94 patients, 53 (56.4%) 
group 1 and 41 (43.6%) group 2 patients, mean age 
30.46±6.28 years and mean androgenetic alopecia 
duration 6.22±5.09 years. 
At month 3 of treatment
None of 94 patients experienced complete recov-
ery during 3 months. Relative recovery was achieved 
in 2.4% of group 1 and 1.9% of group 2 patients, with 
no significant between-group difference (p=0.17). In 
the other words, 98.1% of group 1 patients and 97.6% 
group 2 patients had less than 30% of returning hair 
growth in the thinning area. 
At month 6 of treatment
At the end of 6-month treatment, complete and 
relative recovery did not reveal changes either within 
or between the groups (p=0.99). 
Patient satisfaction rate after 6 months of 
treatment
The patient satisfaction rate based on faster pre-
vention of primary hair loss and appearance of newly 
grown hair was significantly higher in the adenosine 
group (group 2) (p=0.003).
Complications
Four group 1 patients (9.8%) and two group 2 
patients (3.8%) experienced mild complications dur-
ing treatment. One patient in group 1 suffered from 
hair cast and another three patients suffered from 
increased hair loss. Of the two group 2 patients, one 
patient suffered from folliculitis and pruritus each. 
Details are shown in Table 1. 
dISCUSSIon
Despite the low success rate and speculative 
mechanism of minoxidil in returning normal hair 
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Data are presented as n (%) and mean ± standard deviation. 
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Table 1. Recovery rate and satisfaction among patients with androgenetic alopecia following administra-
tion of topical minoxidil 5% and adenosine 0.75% 
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growth cycle and promoting hair growth, it is still the 
first-line treatment for AGA. Minoxidil is an adenosine 
triphosphate (ATP) sensitive potassium channel open-
er that demonstrated some effects on hair growth cy-
cle through different mechanisms like up-regulating 
VEGF expression, stimulating DPC proliferation, in-
creasing DPC survival and preventing DPC apoptosis 
and death (11,14). Expression of VEGF mRNA in DPCs 
varies among different phases of normal hair growth 
cycle, with extreme expression in anagen phase, 
which results in improving dermal papilla vasculariza-
tion. There is strong evidence that minoxidil also has 
effects on improving dermal papilla vascularization 
by overexpression of the VEGF mRNA and resembling 
anagen phase alongside opening potassium chan-
nels (11,15,17). However, Li et al. (16) suggest that 
minoxidil has no direct effect on hair growth and its 
effect is perhaps mediated by adenosine as activation 
of adenosine receptors in cultured DPCs, thus possi-
bly regulating minoxidil-induced production of VEGF. 
Adenosine is an endogenous molecule that regulates 
tissue function via binding to and activating one of 
the four G-protein receptors, A1, A2A, A2B and A3 (18). 
Since the first discovery of the practical effect of ad-
enosine on the cardiac function, adenosine has been 
investigated in many studies, which have revealed 
that it is able to regulate all body organ systems suf-
ficiently (18-21). In this regard, Lino et al. (20) dem-
onstrated that adenosine could stimulate hair growth 
via up-regulating fibroblast growth factor 7 (FGF-7) 
in DPCs. Furthermore, Oura et al. (22) confirmed the 
role of adenosine in stimulation of hair growth and 
thickening of hair shafts in hair growth cycle anagen 
phase and stated that adenosine is useful for treating 
female pattern hair loss as well as androgenetic male 
alopecia. Another interesting finding by Hwang et al. 
(21) in 2012 showed the growth of DPCs and length-
ening of the anagen phase by increasing the cysteine 
level via fibroblast growth factors 2 and 7 in an organ 
culture of mouse vibrissae hair follicles.
In this study, the application of adenosine 0.75% 
solution just once daily showed an equivalent treat-
ment effect to that of 5% minoxidil applied once 
daily in terms of changes in total recovered area by 
newly grown terminal hairs. After 3 months of treat-
ment, relative recovery, i.e. hair growth returning in 
30% to 65% of the thinning area, was not significantly 
different between the groups (p=0.17). In the next 3 
months, at the end of month 6, the relative recovery 
rate did not change either within or between the 
groups (p=0.99) and none of 94 patients achieved 
complete recovery during 6 months of treatment. De-
spite no between-group difference according to re-
covery rate detected by the investigator, the patient 
satisfaction rate was significantly higher in the ade-
nosine group (p=0.003), based on faster prevention 
of primary hair loss and appearance of newly grown 
hairs. These results show that minoxidil and adenos-
ine have the same effect on recovery of hair loss in 
AGA and there is no superiority regarding treatment 
of AGA by adenosine. However, according to the pa-
tient satisfaction rate, adenosine is superior as the 
first-choice treatment for AGA due to faster preven-
tion of hair loss and favorable appearance of newly 
grown hairs. Regardless of differences between the 
groups, none of the recovery rates achieved in this 
study was satisfactory enough. It seems to be re-
lated to some reasons like insufficient application 
of solution by patients or inadequate dosage of mi-
noxidil and adenosine administered, as in the study 
reported by Oura et al. (22), the patients applied 3 cc 
of lotions twice daily for 12 months, which is much 
greater dosage used over a longer treatment period. 
Another factor that seems to have influenced the re-
sults is monotherapy. Future studies may reveal that 
utilizing a combination of minoxidil and adenosine 
just like a combination of minoxidil and finasteride 
can improve and return hair growth with more pig-
mented, thickened, terminal hairs. On the other hand, 
in the present study, the patients were followed up 
for up to 6 months, which was a shorter period than 
the follow up reported from the studies that achieved 
better results. It could easily affect the result of the 
study; for instance, in the study by Oura et al. (22), hair 
appearance improved from 0 in month 6 to 30% in 
month 12 in adenosine group by dermatologist as-
sessment, and from 15% in month 6 to 23% in month 
12 by investigator assessment. 
ConClUSIon
 The conclusion, the present study interestingly 
showed that topical application of a solution with 
0.75% adenosine had the same effects to minoxidil 
5% in the regulation of hair growth cycle and recov-
ery of hair loss. According to the patient satisfaction 
rate, adenosine was superior to minoxidil in the treat-
ment of AGA because it could prevent hair loss faster 
and stimulate hair growth more desirably.
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